Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I0UM
|
|||
| Drug Name |
CTL019
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [1] | |
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2 | [1], [2] | ||
| Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Clinical trial | [2] | ||
| Company |
Novartis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | CAR-T-Cell-Therapy | [1], [2] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Epstein-Barr virus infection | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | PIP3 activates AKT signaling | |||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | Human Complement System | |||
| Signaling by the B Cell Receptor (BCR) | ||||
| PIP3 activates AKT signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03601442) CTL019 Out of Specification MAP for ALL or DLBCL Patients | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.